anti-cd22/anti-cd28 bispecific antibody regn5837
Generic: Anti-CD22/Anti-CD28 Bispecific Antibody REGN5837
anti-cd22/anti-cd28 bispecific antibody regn5837: 1 clinical trial tracked.
anti-cd22/anti-cd28 bispecific antibody regn5837 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-cd22/anti-cd28 bispecific antibody regn5837, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs) of REGN5837 in combination with odronextamab
Interventionalopen91 targetStarted 2023-04Completion 2029-0520 sites · France, Netherlands, Spain, United Kingdom…Regeneron Pharmaceuticals